# Plain Language Summary: Protecting Patients from Deceptive Drug Ads Act

This bill is designed to crack down on misleading advertisements for prescription and over-the-counter medications. Right now, drug companies can run ads on TV, radio, online, and in print that sometimes emphasize benefits while downplaying serious risks or side effects. This bill would require drug manufacturers to present information about their products more fairly and clearly, making sure that any claims about what a drug does are backed up by solid evidence and that warnings about potential dangers are just as prominent as the benefits being advertised.

The main goal is to protect patients from being misled into taking medications based on incomplete or exaggerated information. For example, if a drug company advertises that a medication will help with a certain condition, they'd need to make sure the evidence actually supports that claim, and they'd have to give equal weight to information about serious side effects or risks. This applies to all drug advertising that reaches consumers, whether it's a commercial during a TV show, an ad on social media, or a sponsored post online.

The bill would likely give regulatory agencies (like the FDA) stronger tools to monitor drug advertising and take action against companies that break these rules. For patients, this means you'd have better information to make decisions about your medications. For drug companies, it means they'd need to be more careful and honest in how they market their products. The practical effect is that when you see a drug ad, you should be able to trust that it's giving you the full picture rather than just the parts that make the drug sound good.

Protecting Patients from Deceptive Drug Ads Act

Durbin, Richard J.

Protecting Patients from Deceptive Drug Ads ActThis bill establishes civil penalties for false or misleading communications about prescription drugs by certain entities on social media. It also requires additional disclosures and reporting relating to drug advertisements on social media or via telehealth.The bill’s civil penalties apply when social media influencers or health care providers make communications regarding prescription drugs, using social media platforms, from which they financially benefit that (1) are made knowingly or recklessly and are&nbsp;false or inaccurate, or (2) fail to include the brief summary information (i.e., side effects, contraindications, effectiveness) required in drug advertisements.&nbsp;The Food and Drug Administration (FDA) must issue guidance and publish notice of such enforcement actions. The FDA may notify drug manufacturers when such communications fail to include the brief summary information.The bill also requires&nbsp;telehealth providers (i.e., entities that use telecommunications to bring together patients and drug prescribers or dispensers) to include the brief summary information in prescription drug advertisements.Also, payments from drug manufacturers to health care providers or social media influencers, or from health care providers to influencers, for communications promoting prescription drugs must be reported in accordance with anti-kickback laws for federal health care programs.Additionally,&nbsp;the FDA may conduct market surveillance regarding prescription drug promotion on social media, including analyzing communications and establishing a task force with the Federal Trade Commission.